Diagnosis of and therapy for hepatocellular carcinoma;Diagnostik und Therapie des hepatozellularen Karzinoms

Zeitschrift fur Gastroenterologie

Volumn 51, Issue 11, 2013, Pages 1269-1326

  Greten, T F ^a   Malek, N P ^a   Schmidt, S ^a   Arends, J ^a   Bartenstein, P ^a   Bechstein, W ^a   Bernatik, T ^a   Bitzer, M ^a   Chavan, A ^a   Dollinger, M ^a   Domagk, D ^a   Drognitz, O ^a   Dux, M ^a   Farkas, S ^a   Folprecht, G ^a   Galle, P ^a   Geiler, M ^a   Gerken, G ^a   Habermehl, D ^a   Helmberger, T ^a   Herfarth, K ^a   Hoffmann, R T ^a   Holtmann, M ^a   Huppert, P ^a   Jakobs, T ^a   Keller, M ^a   Klempnauer, J ^a   Kolligs, F ^a   Korber, J ^a   Lang, H ^a   Lehner, F ^a   Lordick, F ^a   Lubienski, A ^a   Manns, M P ^a   Mahnken, A ^a   Mohler M ^a   Monch C ^a   Neuhaus, P ^a   Niederau, C ^a   Ocker, M ^a   Otto, G ^a   Pereira, P ^a   Pott, G ^a   Riemer, J ^a   Ringe, K ^a   Ritterbusch, U ^a   Rummeny, E ^a   Schirmacher, P ^a   Schlitt, H J ^a   Schlottmann, K ^a   Schmitz, V ^a   Schuler, A ^a   Schulze Bergkamen, H ^a   Von Schweinitz, D ^a   Seehofer, D ^a   Sitter, H ^a   Straburg, C P ^a   Stroszczynski, C ^a   Strobel, D ^a   Tannapfel, A ^a   Trojan, J ^a   Van Thiel, I ^a   Vogel, A ^a   Wacker, F ^a   Wedemeyer, H ^a   Wege, H ^a   Weinmann, A ^a   Wittekind, C ^a   Wormann B ^a   Zech, C J ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

hepatitis B; hepatitis C; viral hepatitis

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER THERAPY; DISTANT METASTASIS; HEALTH SERVICE; HUMAN; LIVER CELL CARCINOMA; MORBIDITY; PRACTICE GUIDELINE; QUALITY OF LIFE; GERMANY; LIVER TUMOR; ONCOLOGY; STANDARD;

CARCINOMA, HEPATOCELLULAR; GERMANY; HUMANS; LIVER NEOPLASMS; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC;

EID: 84887834073     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0033-1355841     Document Type: Article

References (571)

1. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology: 2011; 53 03 1020 1022
2. Jemal A. et al. Global cancer statistics. CA Cancer J Clin: 2011; 61 02 69 90
3. Ferlay J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer: 2010; 127 2893 2917
4. El-Serag H. B. et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med: 2003; 139 10 817 823
5. Marrero J. A. et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology: 2002; 36 06 1349 1354 (Pubitemid 35403524)
6. Davila J. A. et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut: 2005; 54 04 533 539 (Pubitemid 40403031)
7. Starley B. Q., Calcagno C. J., Harrison S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology: 2010; 51 05 1820 1832
8. Welzel T. M. et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology: 2011; 54 02 463 471
9. Chen C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA: 2006; 295 01 65 73
10. Tseng T. C. et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology: 2012; 142 05 1140 1149 e3
11. Fattovich G. et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut: 2008; 57 01 84 90
12. Sanchez-Tapias J. M. et al. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology: 2002; 123 06 1848 1856 (Pubitemid 35408309)
13. Yuen M. F. et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol: 2009; 50 01 80 88
14. Yang H. I. et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol: 2011; 12 06 568 574
15. Zhang H. et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet: 2010; 42 09 755 758
16. Perz J. F. et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol: 2006; 45 04 529 538 (Pubitemid 44307383)
17. Tanaka Y. et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology: 2006; 130 03 703 714 (Pubitemid 43374521)
18. Kanwal F. et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology: 2011; 140 04 1182 1188 e1
19. Sangiovanni A. et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology: 2006; 43 06 1303 1310 (Pubitemid 43980109)
20. Lok A. S. et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology: 2009; 136 01 138 148
21. Bruix J. et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology: 2011; 140 07 1990 1999
22. Lok A. S. et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology: 2011; 140 03 840 849; quiz e12
23. Fattovich G. et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology: 2004; 127 05 S35 S50 (Pubitemid 39423368)
24. Kumar V. et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet: 2011; 43 05 455 458
25. Benvegnu L. et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer: 1994; 74 09 2442 2448 (Pubitemid 24320846)
26. Donato F., Boffetta P., Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer: 1998; 75 03 347 354 (Pubitemid 28100034)
27. Fattovich G. et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut: 2000; 46 03 420 426 (Pubitemid 30313398)
28. Ji J. et al. Comparability of cancer identification among Death Registry, Cancer Registry and Hospital Discharge Registry. Int J Cancer: 2012; 131 2085 2093
29. Niro G. A. et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol: 2010; 53 05 834 840
30. Buti M. et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat: 2011; 18 06 434 442
31. O'Shea R. S., Dasarathy S., McCullough A. J. Alcoholic liver disease. Hepatology: 2010; 51 01 307 328
32. Hassan M. M. et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology: 2002; 36 05 1206 1213 (Pubitemid 35253437)
33. Schoniger-Hekele M. et al. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol: 2000; 12 08 941 948 (Pubitemid 30663908)
34. Mandayam S., Jamal M. M., Morgan T. R. Epidemiology of alcoholic liver disease. Semin Liver Dis: 2004; 24 03 217 232 (Pubitemid 39167681)
35. Lu X. L. et al. Risk factors for alcoholic liver disease in China. World J Gastroenterol: 2004; 10 16 2423 2426
36. Niederau C. et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology: 1996; 110 04 1107 1119 (Pubitemid 26113751)
37. Adams P. C. et al. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology: 1997; 25 01 162 166 (Pubitemid 27015004)
38. Bacon B. R. et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology: 2011; 54 01 328 343
39. Philippe M. A., Ruddell R. G., Ramm G. A. Role of iron in hepatic fibrosis: one piece in the puzzle. World J Gastroenterol: 2007; 13 35 4746 4754 (Pubitemid 47455565)
40. Olynyk J. K. Hereditary haemochromatosis: diagnosis and management in the gene era. Liver: 1999; 19 02 73 80 (Pubitemid 29139758)
41. Ertle J. et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer: 2011; 128 10 2436 2443
42. Calle E. E. et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med: 2003; 348 17 1625 1638 (Pubitemid 36459468)
43. Ascha M. S. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology: 2010; 51 06 1972 1978
44. Ratziu V. et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol: 2010; 53 02 372 384
45. Bedogni G. et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology: 2005; 42 01 44 52 (Pubitemid 40911310)
46. Reeves H. VE, Bellentani S. et al. The emerging impact of HCC arising on a background of NAFLD. J Hepatol: 2012; 56 (Suppl 2, A-5): S3
47. Cornberg M. et al. Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline. Z Gastroenterol: 2011; 49 07 871 930
48. Poon D. et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol: 2009; 10 11 1111 1118
49. Stevens C. E. et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med: 1975; 292 15 771 774
50. Okada K. et al. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med: 1976; 294 14 746 749
51. Beasley R. P. et al. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol: 1977; 105 02 94 98 (Pubitemid 8042976)
52. Lee C. et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ: 2006; 33 7537 328 336
53. Hsu H. M. et al. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis: 1999; 179 02 367 370
54. Chang M. H. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med: 1997; 336 26 1855 1859
55. Chang M. H. et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA: 2000; 284 23 3040 3042
56. Reddy S. K. et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology: 2012; 55 1809 1819
57. Sarrazin C. et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol: 2010; 48 02 289 351
58. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol: 2011; 55 02 245 264
59. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol: 2012; 57 01 167 185
60. Liaw Y. F. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med: 2004; 351 15 1521 1531
61. Papatheodoridis G. V. et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol: 2010; 53 02 348 356
62. Papatheodoridis G. V. et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut: 2011; 60 08 1109 1116
63. Hosaka T. et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology: 2013; 58 98 107
64. Hughes S. A., Wedemeyer H., Harrison P. M. Hepatitis delta virus. Lancet: 2011; 378 9785 73 85
65. Wedemeyer H. et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med: 2011; 364 04 322 331
66. Farci P. et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology: 2004; 126 07 1740 1749 (Pubitemid 38736339)
67. Sarrazin C. et al. Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C. Z Gastroenterol: 2012; 50 01 57 72
68. Wedemeyer H. et al. Paradigmatic change in treatment of viral hepatitides. Dtsch Med Wochenschr: 2012; 137 13 640 643
69. Veldt B. J. et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med: 2007; 147 10 677 584
70. Morgan T. R. et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology: 2010; 52 03 833 844
71. Cardoso A. C. et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol: 2010; 52 05 652 657
72. Di Bisceglie A. M. et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med: 2008; 359 23 2429 2441
73. Musso G. et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology: 2010; 52 01 79 104
74. Angelico F. et al. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev: 2007; 01 CD005166
75. Hauner H. BG, Hamann A., Husemann B. et al. Adipositas und Diabetes mellitus. Diabetologie: 2011; 6 S137 S142
76. Calderon R. M. et al. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc: 2010; 85 04 349 356
77. Mummadi R. R. et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol: 2008; 6 12 1396 1402
78. Chavez-Tapia N. C. et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev: 2010; CD007340 10.1002/14651858
79. Sanyal A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med: 2010; 362 18 1675 1685
80. Ratziu V., Caldwell S., Neuschwander-Tetri B. A. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology: 2010; 52 06 2206 2215
81. Lavine J. E. et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA: 2011; 305 16 1659 1668
82. Nkontchou G. et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol: 2010; 53 05 827 833
83. Donadon V. et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int: 2010; 30 05 750 758
84. Lai S. W. et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol: 2012; 107 01 46 52
85. Giovannucci E. et al. Diabetes and cancer: a consensus report. Diabetes Care: 2010; 33 07 1674 1685
86. Zhang Z. J. et al. Metformin for Liver Cancer Prevention in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab: 2012; 97 2347 2353
87. Llovet J. M Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet: 2003; 362 9399 1907 1917 (Pubitemid 37518510)
88. Sarasin F. P., Giostra E., Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med: 1996; 101 04 422 434 (Pubitemid 26392861)
89. Andersson K. L. et al. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol: 2008; 6 12 1418 1424
90. Colombo M. Screening and diagnosis of hepatocellular carcinoma. Liver Int: 2009; 29 01 143 147
91. Velazquez R. F. et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology: 2003; 37 03 520 527 (Pubitemid 36258772)
92. Yang H. I. et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med: 2002; 347 03 168 174
93. Sung J. J. et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther: 2008; 28 09 1067 1077
94. Yoshida H. et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med: 1999; 131 03 174 181 (Pubitemid 29364999)
95. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol: 2012; 56 04 908 943
96. Zoli M. et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer: 1996; 78 05 977 985 (Pubitemid 26284861)
97. Nurnberg D. et al. What's the price of routine sonography - results of an analysis of costs and processes in a district hospital. Ultraschall in Med: 2008; 29 04 405 417
98. Schuler A. et al. Costs of clinical ultrasound examinations - an economical cost calculation and analysis. Ultraschall in Med: 2010; 31 04 379 386
99. Henrion J. et al. Screening for hepatocarcinoma in a cohort with cirrhosis mainly of alcoholic origin. Gastroenterol Clin Biol: 2003; 27 05 534 539 (Pubitemid 36741102)
100. Seitz K. Quality of abdominal ultrasound. Ultraschall in Med: 2006; 27 03 217 219
101. Van Vlierberghe H. et al. BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma. Acta Gastroenterol Belg: 2004; 67 01 14 25 (Pubitemid 38552573)
102. Davila J. A. et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology: 2010; 52 01 132 141
103. Hangiandreou N. J. et al. Four-year experience with a clinical ultrasound quality control program. Ultrasound Med Biol: 2011; 37 08 1350 1357
104. Martensson M. et al. High incidence of defective ultrasound transducers in use in routine clinical practice. Eur J Echocardiogr: 2009; 10 03 389 394
105. Martensson M., Olsson M., Brodin L. A. Ultrasound transducer function: annual testing is not sufficient. Eur J Echocardiogr: 2010; 11 09 801 805
106. Sipila O., Mannila V., Vartiainen E. Quality assurance in diagnostic ultrasound. Eur J Radiol: 2011; 80 02 519 525
107. Rosenfeld E. et al. Investigation of the Suitability of Tissue Phantoms for Testing the Constancy of Ultrasonic Transducer Arrays in Quality Assurance. Ultraschall Med: 2012; 33 289 294
108. Seitz K., Vasilakis D., Ziegler M. Efficiency of a portable B-scan ultrasound device in comparison to a high-end machine in abdominal ultrasound. Results of a pilot study. Ultraschall in Med: 2003; 24 02 96 100 (Pubitemid 36541988)
109. Ziegler C. M. et al. Detection of therapeutically relevant diagnoses made by sonography of the upper abdomen: portable versus high-end sonographic units - a prospective study. Ultraschall in Med: 2004; 25 06 428 432 (Pubitemid 40091491)
110. Ueno S. et al. Preoperative segmentation of the liver, based on 3D CT images, facilitates laparoscopic anatomic hepatic resection for small nodular hepatocellular carcinoma in patients with cirrhosis. Hepatogastroenterology: 2010; 57 101 807 812
111. Seitz K. et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI - a prospective comparison in 269 patients. Ultraschall in Med: 2010; 31 05 492 499
112. Liu G. J. et al. Enhancement pattern of hepatocellular carcinoma: comparison of real-time contrast-enhanced ultrasound and contrast-enhanced computed tomography. Clin Imaging: 2006; 30 05 315 321
113. Seitz K. et al. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreilandertreffen 2008, Davos. Ultraschall in Med: 2009; 30 04 383 389
114. Krug B. et al. Quality control of outpatient imaging examinations in North Rhine-Westphalia, Part II. Fortschr Röntgenstr: 2003; 175 03 346 360 (Pubitemid 36395958)
115. Heese F., Gorg C. The value of highest quality ultrasound as a reference for ultrasound diagnosis. Ultraschall in Med: 2006; 27 03 220 224
116. Zhang B. H., Yang B. H., Tang Z. Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol: 2004; 130 07 417 422
117. Chen J. G. et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen: 2003; 10 04 204 209
118. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol: 2003; 39 06 1076 1084 (Pubitemid 37523784)
119. Singal A. et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther: 2009; 30 01 37 47
120. Trevisani F. et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol: 2001; 34 04 570 575 (Pubitemid 32328514)
121. Teefey S. A. et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology: 2003; 226 02 533 542 (Pubitemid 36313446)
122. Tranquart F. et al. Real-time contrast-enhanced ultrasound in the evaluation of focal liver lesions: diagnostic efficacy and economical issues from a French multicentric study. J Radiol: 2009; 90 01 109 122
123. Strobel D. et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions - diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall in Med: 2008; 29 05 499 505
124. Strobel D. et al. Diagnostic accuracy of CEUS in the differential diagnosis of small (
125. Seitz K. et al. Frequency of tumor entities among liver tumors of unclear etiology initially detected by sonography in the noncirrhotic or cirrhotic livers of 1349 patients. Results of the DEGUM multicenter study. Ultraschall in Med: 2011; 32 06 598 603
126. Marrero J. A. et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology: 2003; 37 05 1114 1121 (Pubitemid 36538688)
127. Sterling R. K. et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol: 2007; 102 10 2196 2205 (Pubitemid 47493844)
128. Sheu J. C. et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology: 1985; 89 02 259 266
129. Ebara M. et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology: 1986; 90 02 289 298 (Pubitemid 16136667)
130. Barbara L. et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology: 1992; 16 01 132 137
131. Trinchet J. C. et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology: 2011; 54 06 1987 1997
132. Wittekind C. H., Meyer H. J. TNM Klassifikation maligner Tumoren. 7. Aufl Weinheim Wiley-VCH: 2010
133. Tumors of the liver and intrahepatic bile ducts. In: Bosman F. D. et al. WHO classification of tumours of the digestive system. Lyon IARC: 2010; 195 262
134. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology: 2009; 49 02 658 664
135. Edmondson H. A., Steiner P. E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer: 1954; 7 03 462 503
136. Nzeako U. C., Goodman Z. D., Ishak K. G. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol: 1996; 105 01 65 75
137. Khalili K. et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol: 2011; 54 04 723 728
138. Kim J. E. et al. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. Am J Roentgenol Am J Roentgenol: 2011; 196 06 W758 W765
139. Forner A. et al. Diagnosis of hepatic nodules 20mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology: 2008; 47 01 97 104 (Pubitemid 351171046)
140. Sangiovanni A. et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut: 2010; 59 05 638 644
141. Baek C. K. et al. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clin Radiol: 2012; 67 02 148 156
142. Addley H. C. et al. Accuracy of hepatocellular carcinoma detection on multidetector CT in a transplant liver population with explant liver correlation. Clin Radiol: 2011; 66 04 349 356
143. Burrel M. et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology: 2003; 38 04 1034 1042 (Pubitemid 37221687)
144. Yu N. C. et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol: 2011; 9 02 161 167
145. Serste T. et al. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology: 2012; 55 03 800 806
146. Mandai M. et al. Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT. Br J Radiol: 2011; 84 1002 499 507
147. Rimola J. et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology: 2009; 50 03 791 798
148. Jang H. J., Kim T. K., Wilson S. R. Small nodules (1-2 cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound. Eur J Radiol: 2009; 72 03 418 424
149. Leoni S. et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol: 2010; 105 03 599 609
150. Iavarone M. et al. Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology: 2010; 52 05 1723 1730
151. Mita K. et al. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol: 2010; 16 33 4187 4192
152. Luca A. et al. Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants. Eur Radiol: 2010; 20 04 898 907
153. Marin D. et al. Detection of hepatocellular carcinoma in patients with cirrhosis: added value of coronal reformations from isotropic voxels with 64-MDCT. Am J Roentgenol Am J Roentgenol: 2009; 192 01 180 187
154. Maetani Y. S. et al. Hepatocellular carcinoma in patients undergoing living-donor liver transplantation. Accuracy of multidetector computed tomography by viewing images on digital monitors. Intervirology: 2008; 51 01 46 51
155. Ronzoni A. et al. Role of MDCT in the diagnosis of hepatocellular carcinoma in patients with cirrhosis undergoing orthotopic liver transplantation. Am J Roentgenol Am J Roentgenol: 2007; 189 04 792 798 (Pubitemid 47479759)
156. Rhee H. et al. Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria. J Magn Reson Imaging: 2012; 35 02 393 398
157. Saito K. et al. Histological grade of differentiation of hepatocellular carcinoma: comparison of the efficacy of diffusion-weighted MRI with T2-weighted imaging and angiography-assisted CT. J Med Imaging Radiat Oncol: 2012; 56 03 261 269
158. Park M. J. et al. Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population. Eur Radiol: 2010; 20 10 2397 2404
159. Talbot J. N. et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med: 2010; 51 11 1699 1706
160. Lee J. E. et al. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. World J Gastroenterol: 2012; 18 23 2979 2987
161. Colli A. et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol: 2006; 101 03 513 523 (Pubitemid 43340927)
162. Di Bisceglie A. M. et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol: 2005; 43 03 434 441 (Pubitemid 41111424)
163. Yamashita T. et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res: 2008; 68 05 1451 1461 (Pubitemid 351346853)
164. Koike Y. et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer: 2001; 91 03 561 569 (Pubitemid 32105702)
165. Tao L. Y. et al. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg: 2010; 76 11 1210 1213
166. Sato Y., Sekine T., Ohwada S. Alpha-fetoprotein-producing rectal cancer: calculated tumor marker doubling time. J Surg Oncol: 1994; 55 04 265 268 (Pubitemid 24143299)
167. Adachi Y. et al. AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology: 2003; 65 02 95 101 (Pubitemid 37025967)
168. N'Kontchou G. et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology: 2009; 50 05 1475 1483
169. Kobayashi M. et al. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res: 2011; 41 11 1036 1045
170. Herszenyi L. et al. Fine-needle biopsy in focal liver lesions: the usefulness of a screening programme and the role of cytology and microhistology. Ital J Gastroenterol: 1995; 27 09 473 478 (Pubitemid 26050951)
171. Durand F. et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol: 2001; 35 02 254 258 (Pubitemid 32803481)
172. Wang P. et al. Diagnostic value and complications of fine needle aspiration for primary liver cancer and its influence on the treatment outcome-a study based on 3011 patients in China. Eur J Surg Oncol: 2008; 34 05 541 546 (Pubitemid 351514890)
173. Caturelli E. et al. Cytological vs microhistological diagnosis of hepatocellular carcinoma: comparative accuracies in the same fine-needle biopsy specimen. Dig Dis Sci: 1996; 41 12 2326 2331
174. Llovet J. M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol: 2008; 48 01 S20 S37
175. Roskams T. Anatomic pathology of hepatocellular carcinoma: impact on prognosis and response to therapy. Clin Liver Dis: 2011; 15 02 245 259, vii-x
176. Wiesner R. H., Freeman R. B., Mulligan D. C. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology: 2004; 127 05 S261 S267 (Pubitemid 39423395)
177. Sugimachi K. et al. Prognostic significance of preoperative imaging in recipients of living donor liver transplantation for hepatocellular carcinoma. Transplantation: 2011; 91 05 570 574
178. Caturelli E. et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol: 2002; 97 02 397 405 (Pubitemid 34160767)
179. Becker-Weidman D. J. et al. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging - comparison to prior same-center results after MR systems improvements. Radiology: 2011; 261 03 824 833
180. Caturelli E. et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut: 2004; 53 09 1356 1362 (Pubitemid 39120127)
181. Maturen K. E. et al. Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. Am J Roentgenol Am J Roentgenol: 2006; 187 05 1184 1187 (Pubitemid 44630819)
182. Bialecki E. S. et al. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol: 2006; 4 03 361 368 (Pubitemid 43343894)
183. Silva M. A. et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut: 2008; 57 11 1592 1596
184. Mullhaupt B. et al. Is tumor biopsy necessary? Liver Transpl: 2011; 17 02 S14 S25
185. Wittekind C., Meyer H. J. TNM. Klassifikation maligner Tumoren. Wiley-VCH, Weinheim: 2010
186. Edge S. BBD, Compton C. C., Fritz A. G. et al., editors. AJCC Cancer Staging Handbook. 7th ed New York Springer: 2010
187. Llovet J. M. et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology: 1998; 27 06 1572 1577 (Pubitemid 28264681)
188. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol: 2006; 44 01 217 231 (Pubitemid 41772537)
189. Hollebecque A. et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther: 2011; 34 10 1193 1201
190. Mazzaferro V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med: 1996; 334 11 693 699 (Pubitemid 26079803)
191. Okuda K. et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer: 1985; 56 04 918 928 (Pubitemid 15228292)
192. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology: 1998; 28 03 751 755
193. Leung T. W. et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer: 2002; 94 06 1760 1769 (Pubitemid 34241115)
194. Kitai S. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology: 2008; 75 01 83 90
195. Llovet J. M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis: 1999; 19 03 329 338
196. Llovet J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst: 2008; 100 10 698 711
197. Greten T. F., Manns M. P. Hepatocellular carcinoma - diagnosis and treatment. Dtsch Med Wochenschr: 2008; 133 38 1907 1910
198. Benson A. B. 3rd et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw: 2009; 7 04 350 391
199. Lang H. et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg: 2007; 205 01 27 36 (Pubitemid 47016970)
200. Laurent C. et al. Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg: 2005; 201 05 656 662 (Pubitemid 41539756)
201. Dupont-Bierre E. et al. Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J Am Coll Surg: 2005; 201 05 663 670 (Pubitemid 41539757)
202. Nishikawa H. et al. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol: 2011; 11 143
203. McWilliams J. P. et al. Percutaneous ablation of hepatocellular carcinoma: current status. J Vasc Interv Radiol: 2010; 21 08 S204 S213
204. Poon R. T. et al. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg: 2000; 231 04 544 551 (Pubitemid 30185862)
205. Shi M. et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg: 2007; 245 01 36 43 (Pubitemid 46035433)
206. Minagawa M. et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg: 2003; 238 05 703 710 (Pubitemid 38182262)
207. Stipa F. et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer: 2006; 106 06 1331 1338 (Pubitemid 43363911)
208. Schlitt H. J. et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol: 1999; 17 01 324 331 (Pubitemid 29022410)
209. Jonas S. et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology: 2001; 33 05 1080 1086 (Pubitemid 32378206)
210. Mazzaferro V. et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol: 2008; 15 04 1001 1007
211. Mazzaferro V. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol: 2009; 10 01 35 43
212. Yi N. J. et al. Current role of surgery in treatment of early stage hepatocellular carcinoma: resection versus liver transplantation. Oncology: 2008; 75 01 124 128
213. Yao F. Y. et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant: 2007; 7 11 2587 2596 (Pubitemid 47561609)
214. Llovet J. M., Schwartz M., Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis: 2005; 25 02 181 200 (Pubitemid 40781071)
215. Yamakado K. et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology: 2008; 247 01 260 266
216. Peng Z. W. et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology: 2012; 262 02 689 700
217. Chua T. C. et al. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int: 2010; 30 02 166 174
218. Morimoto M. et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer: 2010; 116 23 5452 5460
219. Kim J. H. et al. Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol: 2011; 18 06 1624 1629
220. Shibata T. et al. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology: 2009; 252 03 905 913
221. Imamura H. et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. JÂ Hepatobiliary Pancreat Surg: 2005; 12 01 16 22 (Pubitemid 40378835)
222. Stockmann M. et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg: 2009; 250 01 119 125
223. Fong Y. et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg: 1999; 229 06 790 799 discussion 799-800
224. Gouillat C. et al. Resection of hepatocellular carcinoma in cirrhotic patients: longterm results of a prospective study. J Am Coll Surg: 1999; 189 03 282 290 (Pubitemid 29408865)
225. Lang H., Broelsch C. E. Liver resection and transplantation for hepatic tumors. Internist: 2007; 48 01 30 39 (Pubitemid 46181533)
226. Eguchi S. et al. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg: 2011; 98 04 552 557
227. Kim B. W. et al. Risk factors for immediate post-operative fatal recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol: 2006; 12 01 99 104
228. Shah S. A. et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg: 2006; 202 02 275 283 (Pubitemid 43112487)
229. Ohmoto K. et al. Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. J Gastroenterol Hepatol: 2009; 24 02 223 227
230. Ferrari F. S. et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results. Radiol Med: 2007; 112 03 377 393 (Pubitemid 46663984)
231. Wu F. et al. Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Ann Surg Oncol: 2004; 11 12 1061 1069 (Pubitemid 40486652)
232. Lencioni R. et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology: 2005; 234 03 961 967 (Pubitemid 40250844)
233. Llovet J. M. et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology: 2001; 33 05 1124 1129 (Pubitemid 32378211)
234. Mulier S. et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg: 2002; 89 10 1206 1222 (Pubitemid 36002536)
235. de Baere T. et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. Am J Roentgenol Am J Roentgenol: 2003; 181 03 695 700 (Pubitemid 37021837)
236. Rossi S. et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Am J Roentgenol Am J Roentgenol: 1996; 167 03 759 768
237. Guglielmi A. et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg: 2008; 12 01 192 198
238. Vivarelli M. et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg: 2004; 240 01 102 107 (Pubitemid 38808241)
239. Chan A. C. et al. Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg: 2012; 36 01 151 156
240. Chen M. S. et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg: 2006; 243 03 321 328
241. Huang J. et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg: 2010; 252 06 903 912
242. Li L. et al. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol: 2012; 27 01 51 58
243. Hong S. N. et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol: 2005; 39 03 247 252
244. Montorsi M. et al. Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J Gastrointest Surg: 2005; 9 01 62 67; discussion 67-68
245. Cho C. M. et al. The comparative results of radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma. Korean J Hepatol: 2005; 11 01 59 71
246. Ogihara M., Wong L. L., Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB: 2005; 7 03 214 221 (Pubitemid 41535854)
247. Lu M. D. et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi: 2006; 86 12 801 805
248. Lupo L. et al. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? HPB: 2007; 9 06 429 434 (Pubitemid 350215037)
249. Takahashi S. et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology: 2007; 72 01 98 103 (Pubitemid 350256672)
250. Abu-Hilal M. et al. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg: 2008; 12 09 1521 1526
251. Santambrogio R. et al. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class a liver cirrhosis. Ann Surg Oncol: 2009; 16 12 3289 3298
252. Xu H. X. et al. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients. Clin Radiol: 2005; 60 09 1018 1025 (Pubitemid 41194673)
253. Lu M. D. et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol: 2005; 40 11 1054 1060
254. Ikeda M. et al. Radiofrequency ablation and percutaneous ethanol injection in patients with small hepatocellular carcinoma: a comparative study. Jpn J Clin Oncol: 2001; 31 07 322 326 (Pubitemid 32791460)
255. Lencioni R. A. et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology: 2003; 228 01 235 240 (Pubitemid 36736097)
256. Lin S. M. et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology: 2004; 127 06 1714 1723
257. Shiina S. et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology: 2005; 129 01 122 130 (Pubitemid 41002049)
258. Brunello F. et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol: 2008; 43 06 727 735 (Pubitemid 351868714)
259. Orlando A. et al. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol: 2009; 104 02 514 524
260. Castells A. et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology: 1993; 18 05 1121 1126 (Pubitemid 23320442)
261. Gournay J. et al. Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case-control study with cost analysis. Aliment Pharmacol Ther: 2002; 16 08 1529 1538 (Pubitemid 34953594)
262. Daniele B. et al. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study. J Clin Gastroenterol: 2003; 36 01 63 67 (Pubitemid 36005351)
263. Ryu M. et al. Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. Jpn J Clin Oncol: 1997; 27 04 251 257 (Pubitemid 127516775)
264. Arii S. et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology: 2000; 32 06 1224 1229
265. Bruix J. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol: 2001; 35 03 421 430 (Pubitemid 32844200)
266. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology: 2005; 42 05 1208 1236 (Pubitemid 43112690)
267. Livraghi T. et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology: 1999; 210 03 655 661 (Pubitemid 29124024)
268. Lin S. M. et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut: 2005; 54 08 1151 1156
269. Shiina S. et al. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology: 2002; 62 01 64 68 (Pubitemid 34702022)
270. Minami Y., Kudo M. Radiofrequency ablation of hepatocellular carcinoma: Current status. World J Radiol: 2010; 2 11 417 424
271. Goldberg S. N. et al. Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol: 1998; 9 01 101 111 (Pubitemid 28049697)
272. Ballem N. et al. Laparoscopic radiofrequency ablation of unresectable hepatocellular carcinoma: long-term follow-up. HPB: 2008; 10 05 315 320
273. Curley S. A. et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg: 2000; 232 03 381 391
274. Topal B. et al. Morbidity and mortality of laparoscopic vs. open radiofrequency ablation for hepatic malignancies. Eur J Surg Oncol: 2007; 33 05 603 607 (Pubitemid 46746544)
275. Minami Y. et al. Treatment of large and/or multiple hepatic malignancies: open surgical approaches of radiofrequency ablation. Hepatogastroenterology: 2007; 54 80 2358 2360
276. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology: 2010; 78 01 113 124
277. Izumi N. Recent advances of radiofrequency ablation for early hepatocellular carcinoma. J Gastroenterol Hepatol: 2011; 26 01 115 122
278. Crocetti L. et al. Peri-intraprocedural imaging: US, CT, and MRI. Abdom Imaging: 2011; 36 648 660
279. Claudon M. et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall in Med: 2008; 29 01 28 44 (Pubitemid 351294171)
280. Schraml C. et al. Diagnostic performance of contrast-enhanced computed tomography in the immediate assessment of radiofrequency ablation success in colorectal liver metastases. Abdom Imaging: 2008; 33 06 643 651
281. Pandeya G. D. et al. Feasibility of noninvasive temperature assessment during radiofrequency liver ablation on computed tomography. JÂ Comput Assist Tomogr: 2011; 35 03 356 360
282. Clasen S., Pereira P. L. Magnetic resonance guidance for radiofrequency ablation of liver tumors. J Magn Reson Imaging: 2008; 27 02 421 433 (Pubitemid 351214048)
283. Terraz S. et al. Radiofrequency ablation of small liver malignancies under magnetic resonance guidance: progress in targeting and preliminary observations with temperature monitoring. Eur Radiol: 2010; 20 04 886 897
284. Mazzaferro V. et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg: 2004; 240 05 900 909 (Pubitemid 39425785)
285. Pompili M. et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl: 2005; 11 09 1117 1126 (Pubitemid 41341763)
286. Wong L. L. et al. Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transplant: 2004; 18 03 227 234 (Pubitemid 38744844)
287. Yao F. Y. et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology: 2008; 48 03 819 827
288. Graziadei I. W. et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl: 2003; 9 06 557 563 (Pubitemid 36701690)
289. Majno P. E. et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg: 1997; 226 06 688 701; discussion 701-703
290. Millonig G. et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl: 2007; 13 02 272 279 (Pubitemid 46351654)
291. Otto G. et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl: 2006; 12 08 1260 1267 (Pubitemid 44194595)
292. Chapman W. C. et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg: 2008; 248 04 617 625
293. Fisher R. A. et al. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant: 2004; 18 05 502 512 (Pubitemid 39264345)
294. Llovet J. M. et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut: 2002; 50 01 123 128 (Pubitemid 34028315)
295. Yao F. Y. et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl: 2003; 9 07 684 692 (Pubitemid 36874454)
296. Hayashi P. H. et al. Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant: 2004; 4 05 782 787 (Pubitemid 38637578)
297. Helmberger T. et al. Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion: 2007; 75 02 104 112 (Pubitemid 47343961)
298. Porrett P. M. et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl: 2006; 12 04 665 673
299. Ravaioli M. et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation: 2004; 78 12 1780 1786 (Pubitemid 40041645)
300. Cornberg M. et al. The German guideline for the management of hepatitis B virus infection: short version. J Viral Hepat: 2008; 15 01 1 21
301. Shen Y. C. et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol: 2010; 52 06 889 894
302. Breitenstein S. et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg: 2009; 96 09 975 981
303. Mazzaferro V. et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology: 2006; 44 06 1543 1554 (Pubitemid 44970357)
304. Ji J. et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med: 2009; 361 15 1437 1447
305. Zhang C. H. et al. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer: 2009; 124 12 2982 2988
306. Miyake Y. et al. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat: 2010; 17 04 287 292
307. Samuel M. et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev: 2009; 01 CD001199
308. Zimmerman M. A. et al. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transplant Proc: 2007; 39 10 3276 3280 (Pubitemid 350258646)
309. Zimmerman M. A. et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int: 2007; 20 09 747 753 (Pubitemid 47221058)
310. Toso C. et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation: 2007; 83 09 1162 1168 (Pubitemid 46743675)
311. Chinnakotla S. et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl: 2009; 15 12 1834 1842
312. Vivarelli M. et al. Sirolimus in liver transplant recipients: a large single-center experience. Transplant Proc: 2010; 42 07 2579 2584
313. Toso C. et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology: 2010; 51 04 1237 1243
314. Kneteman N. M. et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl: 2004; 10 10 1301 1311 (Pubitemid 39406087)
315. Zimmerman M. A. et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl: 2008; 14 05 633 638 (Pubitemid 351696274)
316. Schnitzbauer A. A. et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer: 2010; 10 190
317. Guglielmi A. et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol: 2008; 103 03 597 604 (Pubitemid 351405970)
318. Yoon J. H. et al. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol: 2010; 21 03 348 356
319. Vauthey J. N. et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB: 2010; 12 05 289 299
320. Schima W. et al. Post-treatment imaging of liver tumours. Cancer Imaging: 2007; 7 Spec No A S28 S36 (Pubitemid 350143144)
321. Frieser M. et al. Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies. Ultraschall in Med: 2011; 32 02 148 153
322. Schacherer D. et al. Transabdominal ultrasound with echoenhancement by contrast media in the diagnosis of hepatocellular carcinoma. Dig Dis: 2009; 27 02 109 113
323. Lencioni R., Piscaglia F., Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol: 2008; 48 05 848 857
324. Crocetti L., de Baere T., Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol: 2010; 33 01 11 17
325. Tsai M. C. et al. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol: 2010; 25 03 605 612
326. Willatt J. M. et al. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology: 2008; 247 02 311 330
327. Escartin A. et al. Recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc: 2007; 39 07 2308 2310 (Pubitemid 47418151)
328. Lo C. M. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology: 2002; 35 05 1164 1171
329. Llovet J. M. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet: 2002; 359 9319 1734 1739 (Pubitemid 34607087)
330. Wible B. C. et al. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol: 2010; 21 07 1024 1030
331. Bronowicki J. P. et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer: 1994; 74 01 16 24
332. Stefanini G. F. et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer: 1995; 75 10 2427 2434
333. Huppert P. E. et al. Chemoembolization of hepatocellular carcinomas: which factors determine therapeutic response and survival? Fortschr Röntgenstr: 2004; 176 03 375 385 (Pubitemid 38391371)
334. Herber S. et al. [Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis - experiences]. Zentralbl Chir: 2007; 132 04 306 315
335. Okazaki M. et al. Intraperitoneal hemorrhage from hepatocellular carcinoma: emergency chemoembolization or embolization. Radiology: 1991; 180 03 647 651
336. Chung J. W. et al. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. Am J Roentgenol Am J Roentgenol: 1995; 165 02 315 321
337. Georgiades C. S. et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol: 2005; 16 12 1653 1659 (Pubitemid 44431162)
338. Luo J. et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol: 2011; 18 02 413 420
339. Chung G. E. et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology: 2011; 258 02 627 634
340. Uraki J. et al. Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors. Eur J Radiol: 2004; 51 01 12 18 (Pubitemid 38746891)
341. Zhang X. B. et al. Hepatocellular carcinoma invading the main portal vein: treatment with transcatheter arterial chemoembolization and portal vein stenting. Cardiovasc Intervent Radiol: 2009; 32 01 52 61
342. Kim J. H. et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther: 2009; 29 12 1291 1298
343. Marelli L. et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol: 2007; 30 01 6 25 (Pubitemid 44900485)
344. Doci R. et al. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer: 1988; 61 10 1983 1987
345. Atiq O. T. et al. Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. Cancer: 1992; 69 04 920 924
346. Ikeda M. et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology: 2004; 66 01 24 31 (Pubitemid 38410676)
347. Hamada A. et al. Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors. J Vasc Interv Radiol: 2004; 15 08 835 841 (Pubitemid 39063223)
348. Kirchhoff T. D. et al. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol: 2006; 32 02 201 207 (Pubitemid 43257124)
349. Lammer J. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol: 2010; 33 01 41 52
350. Malagari K. et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol: 2010; 33 03 541 551
351. Reyes D. K. et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J: 2009; 15 06 526 532
352. Salem R. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology: 2010; 138 01 52 64
353. Vente M. A. et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol: 2009; 19 04 951 959
354. Lau W. Y. et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys: 2012; 82 01 401 407
355. Ernst O. et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. Am J Roentgenol Am J Roentgenol: 1999; 172 01 59 64 (Pubitemid 29028431)
356. Shim J. H. et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology: 2012; 262 02 708 718
357. Therasse P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst: 2000; 92 03 205 216
358. Lencioni R., Llovet J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis: 2010; 30 01 52 60
359. Hunt S. J. et al. Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol: 2009; 20 01 30 38
360. Mornex F. et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies - mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys: 2006; 66 04 1152 1158 (Pubitemid 44740208)
361. Skinner H. D. et al. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol: 2011; 50 08 1191 1198
362. Andolino D. L. et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys: 2011; 81 04 e447 e453
363. Law A. L. et al. Treatment of primary liver cancer using highly-conformal radiotherapy with kV-image guidance and respiratory control. Radiother Oncol: 2012; 102 01 56 61
364. Kato H. et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys: 2004; 59 05 1468 1476 (Pubitemid 38954070)
365. Komatsu S. et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer: 2011; 117 21 4890 4904
366. Bush D. A. et al. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology: 2004; 127 05 S189 S193 (Pubitemid 39423387)
367. Bush D. A. et al. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer: 2011; 117 13 3053 3059
368. Kawashima M. et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol: 2005; 23 09 1839 1846 (Pubitemid 46211361)
369. Worns M. A. et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol: 2009; 43 05 489 495
370. Schutte K. et al. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Digestion: 2011; 83 04 275 282
371. Miller A. A. et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol: 2009; 27 11 1800 1805
372. Yau T. et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer: 2009; 115 02 428 436
373. Shim J. H. et al. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol: 2009; 135 04 617 625
374. Pinter M. et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther: 2011; 34 08 949 959
375. Cheng A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol: 2009; 10 01 25 34
376. Kim J. E. et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol: 2011; 68 05 1285 1290
377. Llovet J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med: 2008; 359 04 378 390
378. Ozenne V. et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol: 2010; 22 09 1106 1110
379. Abou-Alfa G. K. et al. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res: 2011; 4 02 40 44
380. Pinter M. et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist: 2009; 14 01 70 76
381. Iavarone M. et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology: 2011; 54 06 2055 2063
382. Abou-Alfa G. K. et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol: 2006; 24 26 4293 4300 (Pubitemid 46630787)
383. Worns M. A. et al. Systemic therapies in hepatocellular carcinoma. Dig Dis: 2009; 27 02 175 188
384. Personeni N. et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol: 2012; 57 01 101 107
385. Barbare J. C. et al. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer: 2009; 45 10 1788 1797
386. Verset G. et al. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer: 2007; 97 05 582 588 (Pubitemid 47339881)
387. Gish R. G. et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol: 2007; 25 21 3069 3075
388. Yeo W. et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst: 2005; 97 20 1532 1538 (Pubitemid 41631953)
389. Chow P. K. et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology: 2002; 36 05 1221 1226 (Pubitemid 35253439)
390. Martinez Cerezo F. J. et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol: 1994; 20 06 702 706
391. Engstrom P. F. et al. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer: 1990; 65 12 2641 2643 (Pubitemid 20179536)
392. Farinati F. et al. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol: 1990; 11 03 297 301
393. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet: 1998; 352 9121 17 20
394. Llovet J. M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology: 2003; 37 02 429 442 (Pubitemid 36152543)
395. Riestra S. et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol: 1998; 26 03 200 203 (Pubitemid 28211364)
396. Nowak A. K., Findlay M., Culjak G. Tamoxifen for hepatocellular carcinoma (Review). Clinical Trials: 2009; Published Online: January 21, 2009
397. Villa E. et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res: 1996; 56 17 3883 3885 (Pubitemid 26284732)
398. Villa E. et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res: 1995; 55 03 498 500
399. Chow P. K. et al. Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. Br J Cancer: 2011; 105 07 945 952
400. Kouroumalis E. et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut: 1998; 42 03 442 447 (Pubitemid 28197039)
401. Yuen M. F. et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology: 2002; 36 03 687 691
402. Slijkhuis W. A. et al. Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol: 2005; 39 04 333 338 (Pubitemid 40393250)
403. Cebon J. et al. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer: 2006; 95 07 853 361
404. Becker G. et al. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology: 2007; 45 01 9 15
405. Kern M. A. et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology: 2002; 36 04 885 894
406. Malka D. et al. Antitumoral effect of celecoxib in hepatocellular carcinoma. J Clin Oncol: 2005; 23 21 4805 4806 (Pubitemid 46224096)
407. Bassiouny A. R., Zaky A., Neenaa H. M. Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients. Ann Hepatol: 2010; 9 04 410 418
408. Greten T. F., Manns M. P., Korangy F. Immunotherapy of HCC. Rev Recent Clin Trials: 2008; 3 01 31 39 (Pubitemid 351267024)
409. Zhu A. X. et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol: 2009; 27 18 3027 3035
410. Koeberle D. et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist: 2010; 15 03 285 292
411. Faivre S. et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol: 2009; 10 08 794 800
412. Siegel A. B. et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol: 2008; 26 18 2992 2998
413. Thomas M. B. et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. JÂ Clin Oncol: 2009; 27 06 843 850
414. Yau T. et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs: 2012; 30 2384 2390
415. Zhu A. X. et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol: 2006; 24 12 1898 1903 (Pubitemid 46638989)
416. Hsu C. H. et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer: 2010; 102 06 981 986
417. Sun W. et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer: 2011; 117 14 3187 3192
418. Philip P. A. et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol: 2005; 23 27 6657 6663 (Pubitemid 46190260)
419. Thomas M. B. et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer: 2007; 110 05 1059 1067 (Pubitemid 47312872)
420. Chiorean E. G. et al. Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101. Oncologist: 2012; 17 01 e13 e26
421. Zhu A. X. et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer: 2007; 110 03 581 589 (Pubitemid 47106147)
422. Asnacios A. et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer: 2008; 112 12 2733 2739 (Pubitemid 351969218)
423. Sanoff H. K. et al. Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res: 2011; 4 03 78 83
424. Finn R. S. et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res: 2012; 18 07 2090 2098
425. Kim K. W., Lee J. M., Choi B. I. Assessment of the treatment response of HCC. Abdom Imaging: 2011; 36 03 300 314
426. Maksimovic O. et al. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. Am J Roentgenol Am J Roentgenol: 2010; 194 01 5 14
427. Horger M. et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer: 2009; 9 208
428. Spira D. et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol: 2011; 18 01 89 96
429. Riaz A. et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol: 2011; 54 04 695 704
430. Evert M., Dombrowski F. Hepatocellular carcinoma in the non-cirrhotic liver. Pathologe: 2008; 29 01 47 52
431. Nagahama H. et al. Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma. Jpn J Clin Oncol: 1997; 27 05 321 324 (Pubitemid 127520821)
432. Leung T. W. et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer: 2002; 94 02 421 427 (Pubitemid 34081372)
433. Lai C. L. et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer: 1988; 62 03 479 483
434. Jelic S., Sotiropoulos G. C. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: 2010; 21 05 v59 v64
435. Nowak A. K., Chow P. K., Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer: 2004; 40 10 1474 1484 (Pubitemid 38757734)
436. Thomas M. B. et al. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol: 2008; 15 04 1008 1014
437. Edeline J. et al. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J Gastroenterol: 2009; 15 06 713 716
438. Abou-Alfa G. K. et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA: 2010; 304 19 2154 2160
439. Yeo W. et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol: 2004; 15 11 1661 1666 (Pubitemid 39562607)
440. Pinna A. D. et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology: 1997; 26 04 877 883 (Pubitemid 27413652)
441. Hemming A. W. et al. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg: 1997; 1 04 342 346 (Pubitemid 127432780)
442. Patt Y. Z. et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol: 2003; 21 03 421 427 (Pubitemid 46606469)
443. Plauth M. et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr: 2006; 25 02 285 294 (Pubitemid 43811683)
444. Mendenhall C. L. et al. VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. Am J Clin Nutr: 1986; 43 02 213 218 (Pubitemid 16099803)
445. Mendenhall C. L. et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology: 1993; 17 04 564 576 (Pubitemid 23115499)
446. Mendenhall C. L. et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. JPEN J Parenter Enteral Nutr: 1995; 19 04 258 265
447. Arends J. et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr: 2006; 25 02 245 259 (Pubitemid 43811685)
448. Dewys W. D. et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med: 1980; 69 04 491 497 (Pubitemid 10018703)
449. Andreyev H. J. et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer: 1998; 34 04 503 509 (Pubitemid 28179346)
450. van Eys J. Effect of nutritional status on responses to therapy. Cancer Res: 1982; 42 02 747s 753s (Pubitemid 12159248)
451. Ollenschlager G. et al. Nutritional behaviour and quality of life during oncological polychemotherapy: results of a prospective study on the efficacy of oral nutrition therapy in patients with acute leukaemia. Eur J Clin Invest: 1992; 22 08 546 553
452. Tubiana M. et al. Prognostic factors in 454 cases of Hodgkin's disease. Cancer Res: 1971; 31 11 1801 1810
453. Swenerton K. D. et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res: 1979; 39 05 1552 1562 (Pubitemid 9172673)
454. Pedersen H. et al. The prognostic significance of weight loss and its integration in stage-grouping of oesophageal cancer. Acta Chir Scand: 1982; 148 04 363 366 (Pubitemid 12078251)
455. Fein R. et al. Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy. Cancer: 1985; 56 10 2512 2518 (Pubitemid 16202452)
456. van Bokhorst-de van der S. et al. The impact of nutritional status on the prognoses of patients with advanced head and neck cancer. Cancer: 1999; 86 03 519 527 (Pubitemid 29347416)
457. Bunout D. et al. Nutritional support in hospitalized patients with alcoholic liver disease. Eur J Clin Nutr: 1989; 43 09 615 621 (Pubitemid 19261093)
458. Kearns P. J. et al. Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology: 1992; 102 01 200 205
459. Le Cornu KA et al. A prospective randomized study of preoperative nutritional supplementation in patients awaiting elective orthotopic liver transplantation. Transplantation: 2000; 69 07 1364 1369
460. Hirsch S. et al. Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis. JPEN J Parenter Enteral Nutr: 1993; 17 02 119 124 (Pubitemid 23073279)
461. Kondrup J., Muller M. J. Energy and protein requirements of patients with chronic liver disease. J Hepatol: 1997; 27 01 239 247 (Pubitemid 27357083)
462. Cabre E. et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology: 1990; 98 03 715 720 (Pubitemid 20069709)
463. Knox L. S. et al. Energy expenditure in malnourished cancer patients. Ann Surg: 1983; 197 02 152 162 (Pubitemid 13184440)
464. Dempsey D. T. et al. Energy expenditure in malnourished gastrointestinal cancer patients. Cancer: 1984; 53 06 1265 1273 (Pubitemid 14198883)
465. Dempsey D. T. et al. Energy expenditure in malnourished patients with colorectal cancer. Arch Surg: 1986; 121 07 789 795 (Pubitemid 16041692)
466. Hansell D. T., Davies J. W., Burns H. J. Effects of hepatic metastases on resting energy expenditure in patients with colorectal cancer. Br J Surg: 1986; 73 08 659 662 (Pubitemid 16039372)
467. Fredrix E. W. et al. Effect of different tumor types on resting energy expenditure. Cancer Res: 1991; 51 22 6138 6141
468. Moses A. W. et al. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer: 2004; 90 05 996 1002 (Pubitemid 38495818)
469. Gibney E. et al. Total energy expenditure in patients with small-cell lung cancer: results of a validated study using the bicarbonate-urea method. Metabolism: 1997; 46 12 1412 1417 (Pubitemid 28053205)
470. Staal-Van Den Brekel A. J. et al. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol: 1995; 13 10 2600 2605
471. Cabre E. et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology: 2000; 32 01 36 42 (Pubitemid 30432363)
472. Plauth M. et al. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr: 1997; 16 02 43 55 (Pubitemid 27249892)
473. Smith J. et al. Enteral hyperalimentation in undernourished patients with cirrhosis and ascites. Am J Clin Nutr: 1982; 35 01 56 72 (Pubitemid 12126588)
474. Cordoba J. et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol: 2004; 41 01 38 43 (Pubitemid 39005150)
475. de Ledinghen V. et al. Early feeding or enteral nutrition in patients with cirrhosis after bleeding from esophageal varices? A randomized controlled study. Dig Dis Sci: 1997; 42 03 536 541 (Pubitemid 27148338)
476. Loser C., Folsch U. R. Guidelines for treatment with percutaneous endoscopic gastrostomy. German Society of Digestive and Metabolic Diseases. Z Gastroenterol: 1996; 34 06 404 408
477. Weimann A. et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. Clin Nutr: 2006; 25 02 224 244 (Pubitemid 43832525)
478. Shukla H. S. et al. Enteral hyperalimentation in malnourished surgical patients. Indian J Med Res: 1984; 80 339 346
479. Von Meyenfeldt M. F. et al. Perioperative nutritional support: a randomised clinical trial. Clin Nutr: 1992; 11 04 180 186
480. Perioperative total parenteral nutrition in surgical patients. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. NÂ Engl J Med: 1991; 325 08 525 532
481. Heyland D. K. et al. Total parenteral nutrition in the surgical patient: a meta-analysis. Can J Surg: 2001; 44 02 102 111 (Pubitemid 32422708)
482. Reilly J. et al. Nutritional support after liver transplantation: a randomized prospective study. JPEN J Parenter Enteral Nutr: 1990; 14 04 386 391 (Pubitemid 20219607)
483. Kanematsu T. et al. Lack of preventive effect of branched-chain amino acid solution on postoperative hepatic encephalopathy in patients with cirrhosis: a randomized, prospective trial. Surgery: 1988; 104 03 482 488
484. Hu Q. G., Zheng Q. C. The influence of Enteral Nutrition in postoperative patients with poor liver function. World J Gastroenterol: 2003; 9 04 843 846
485. Lewis S. J. et al. Early enteral feeding versus nil by mouth after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. BMJ: 2001; 323 7316 773 776 (Pubitemid 32946761)
486. Marik P. E., Zaloga G. P. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med: 2001; 29 12 2264 2270 (Pubitemid 34038156)
487. Schilder J. M. et al. A prospective controlled trial of early postoperative oral intake following major abdominal gynecologic surgery. Gynecol Oncol: 1997; 67 03 235 240 (Pubitemid 28034628)
488. Stewart B. T. et al. Early feeding after elective open colorectal resections: a prospective randomized trial. Aust N Z J Surg: 1998; 68 02 125 128 (Pubitemid 28254927)
489. Moiniche S. et al. Convalescence and hospital stay after colonic surgery with balanced analgesia, early oral feeding, and enforced mobilisation. Eur J Surg: 1995; 161 04 283 288
490. Kremer A. E. et al. Pathogenesis and treatment of pruritus in cholestasis. Drugs: 2008; 68 15 2163 2182
491. AWMF-S2k-Leitlinie (AWMF-Register Nr. 013/048, Version 2.1/2011): Diagnostisches und therapeutisches Vorgehen bei chronischem Pruritus.
492. Stander S. et al. Pathogenesis of pruritus. J Dtsch Dermatol Ges: 2011; 9 06 456 463
493. Bachs L. et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet: 1989; 1 8638 574 576 (Pubitemid 19074002)
494. Ghent C. N., Carruthers S. G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology: 1988; 94 02 488 493 (Pubitemid 18054790)
495. Terg R. et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol: 2002; 37 06 717 722 (Pubitemid 35404208)
496. Bergasa N. V. et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology: 1992; 102 02 544 549
497. Mayo M. J. et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology: 2007; 45 03 666 674 (Pubitemid 46450618)
498. Lindor K. D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med: 1997; 336 10 691 695
499. Talwalkar J. A. et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol: 2003; 1 04 297 302 (Pubitemid 37254457)
500. Zapata R. et al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience. Liver Int: 2005; 25 03 548 554 (Pubitemid 40861904)
501. Lemyze M. et al. Aerobic capacity in patients with chronic liver disease: Very modest effect of liver transplantation. Presse Med: 2010; 39 07 e174 e181
502. Epstein S. K. et al. Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl: 2004; 10 03 418 424 (Pubitemid 38380318)
503. van Ginneken B. T. et al. Physical fitness, fatigue, and quality of life after liver transplantation. Eur J Appl Physiol: 2007; 100 03 345 353
504. Cramp F., Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2008 Apr 16; (2): CD 006145. doi: 10.1002/14651858. CD 006145.pub2
505. van den Berg-Emons R. et al. Fatigue is a major problem after liver transplantation. Liver Transpl: 2006; 12 06 928 933
506. van Ginneken B. T. et al. Effects of a rehabilitation programme on daily functioning, participation, health-related quality of life, anxiety and depression in liver transplant recipients. Disabil Rehabil: 2010; 32 25 2107 2112
507. Schwibbe G. Changes in quality of life in oncological patients in the course of an inpatient after-care program. Rehabilitation: 1991; 30 02 55 62
508. Gartner U. et al. Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation. Med Klin: 1996; 91 08 501 508 (Pubitemid 26267703)
509. Sanson-Fisher R. et al. The unmet supportive care needs of patients with cancer. Supportive Care Review Group. Cancer: 2000; 88 01 226 237
510. Kleeberg U. R. et al. Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study. Support Care Cancer: 2005; 13 05 303 310 (Pubitemid 40674835)
511. Fallowfield L., Jenkins V. Communicating sad, bad, and difficult news in medicine. Lancet: 2004; 363 9405 312 319 (Pubitemid 38142417)
512. Ong L. M. et al. Doctor-patient communication and cancer patients' quality of life and satisfaction. Patient Educ Couns: 2000; 41 02 145 156 (Pubitemid 30665573)
513. de Haes H., Teunissen S. Communication in palliative care: a review of recent literature. Curr Opin Oncol: 2005; 17 04 345 350 (Pubitemid 40904419)
514. Fukui S. et al. A randomized study assessing the efficacy of communication skill training on patients' psychologic distress and coping: nurses' communication with patients just after being diagnosed with cancer. Cancer: 2008; 113 06 1462 1470
515. Razavi D. et al. How to optimize physicians' communication skills in cancer care: results of a randomized study assessing the usefulness of posttraining consolidation workshops. J Clin Oncol: 2003; 21 16 3141 3149 (Pubitemid 46606296)
516. Lienard A. et al. Factors that influence cancer patients' and relatives' anxiety following a three-person medical consultation: impact of a communication skills training program for physicians. Psychooncology: 2008; 17 05 488 496 (Pubitemid 351802758)
517. Edwards A., Elwyn G. Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision. Health Expect: 2006; 9 04 307 320 (Pubitemid 44710744)
518. Butow P. et al. Shared decision making coding systems: how do they compare in the oncology context? Patient Educ Couns: 2010; 78 02 261 268
519. Gordon E. J. et al. Are informed consent forms for organ transplantation and donation too difficult to read? Clin Transplant: 2012; 26 02 275 283
520. Volk M. L. et al. Patient decision making about organ quality in liver transplantation. Liver Transpl: 2011; 17 12 1387 1393
521. Rodrigue J. R., Hanto D. W., Curry M. P. Patients' expectations and success criteria for liver transplantation. Liver Transpl: 2011; 17 11 1309 1317
522. Butow P. N., Tattersall M. H., Goldstein D. Communication with cancer patients in culturally diverse societies. Ann N Y Acad Sci: 1997; 809 317 329 (Pubitemid 27190162)
523. Dowsett S. M. et al. Communication styles in the cancer consultation: preferences for a patient-centred approach. Psychooncology: 2000; 9 02 147 156 (Pubitemid 30237281)
524. Epstein R. M. Making communication research matter: what do patients notice, what do patients want, and what do patients need? Patient Educ Couns: 2006; 60 03 272 278 (Pubitemid 43287931)
525. Zachariae R. et al. Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease. Br J Cancer: 2003; 88 05 658 665 (Pubitemid 36411439)
526. Strasser F. et al. Impact of physician sitting versus standing during inpatient oncology consultations: patients' preference and perception of compassion and duration. A randomized controlled trial. J Pain Symptom Manage: 2005; 29 05 489 497 (Pubitemid 40724742)
527. Fogarty L. A. et al. Can 40 seconds of compassion reduce patient anxiety? J Clin Oncol: 1999; 17 01 371 379 (Pubitemid 29022416)
528. Venetis M. K. et al. An evidence base for patient-centered cancer care: a meta-analysis of studies of observed communication between cancer specialists and their patients. Patient Educ Couns: 2009; 77 03 379 383
529. Arora N. K. Interacting with cancer patients: the significance of physicians' communication behavior. Soc Sci Med: 2003; 57 05 791 806 (Pubitemid 36870719)
530. Arora V. et al. Communication failures in patient sign-out and suggestions for improvement: a critical incident analysis. Qual Saf Health Care: 2005; 14 06 401 407 (Pubitemid 41820063)
531. Girgis A. et al. Impact of two supportive care interventions on anxiety, depression, quality of life, and unmet needs in patients with nonlocalized breast and colorectal cancers. J Clin Oncol: 2009; 27 36 6180 6190
532. Detmar S. B. et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA: 2002; 288 23 3027 3034 (Pubitemid 35471165)
533. Velikova G. et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol: 2004; 22 04 714 724 (Pubitemid 41095076)
534. Taenzer P. et al. Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients. Psychooncology: 2000; 9 03 203 213 (Pubitemid 30392195)
535. Velikova G. et al. Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial. Eur J Cancer: 2010; 46 13 2381 2388
536. McLachlan S. A. et al. Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer. JÂ Clin Oncol: 2001; 19 21 4117 4125
537. Bonnetain F. et al. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res: 2008; 17 06 831 843
538. Yeo W. et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol: 2006; 17 07 1083 1089 (Pubitemid 43985243)
539. Gotay C. C. et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol: 2008; 26 08 1355 1363
540. Quinten C. et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol: 2009; 10 09 865 871
541. Bullinger M. German translation and psychometric testing of the SF-36Â Health Survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. Soc Sci Med: 1995; 41 10 1359 1366
542. Aaronson N. K. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst: 1993; 85 05 365 376 (Pubitemid 23073154)
543. Cella D. F. et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol: 1993; 11 03 570 579 (Pubitemid 23071057)
544. Ware D. L. The SF-36 health survey. In: Spilker B. (ed) Quality of life and pharmaeconomics in clinical trials. Philadelphia Lippincott-Raven: 1996; 337 346
545. Blazeby J. M. et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer: 2004; 40 15 2260 2268 (Pubitemid 39348876)
546. Steel J. L. et al. Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general population. Qual Life Res: 2007; 16 02 203 215 (Pubitemid 46088354)
547. Fan S. Y., Eiser C., Ho M. C. Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol: 2010; 8 07 559 564 e1-10
548. Lai Y. H. et al. Fatigue experiences in hepatocellular carcinoma patients during six weeks of stereotactic radiotherapy. Oncologist: 2007; 12 02 221 230
549. Tsai L. Y. et al. Fatigue and its associated factors in hospice cancer patients in Taiwan. Cancer Nurs: 2007; 30 01 24 30
550. Zabora J. et al. The prevalence of psychological distress by cancer site. Psychooncology: 2001; 10 01 19 28 (Pubitemid 32106774)
551. Sharpe M. et al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer: 2004; 90 02 314 320 (Pubitemid 38250622)
552. Keller M. et al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach. Ann Oncol: 2004; 15 08 1243 1249 (Pubitemid 39199312)
553. Singer S. et al. Screening for mental disorders in laryngeal cancer patients: a comparison of 6 methods. Psychooncology: 2008; 17 03 280 286 (Pubitemid 351410766)
554. Mitchell A. J. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol: 2011; 12 02 160 174
555. Mehnert A. et al. Prevalence of mental disorders, psychosocial distress and need for psychosocial support in cancer patients: study protocol of an epidemiological multi-center study. BMC Psychiatry: 2012; 12 01 70
556. Miovic M., Block S. Psychiatric disorders in advanced cancer. Cancer: 2007; 110 08 1665 1676 (Pubitemid 47557291)
557. Fallowfield L. et al. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer: 2001; 84 08 1011 1015 (Pubitemid 32448494)
558. Sollner W. et al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling? Br J Cancer: 2001; 84 02 179 185 (Pubitemid 32113442)
559. Patrick D. National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression and fatigue. J Natl Cancer Inst: 2003; 95 1110 1117
560. Strong V. et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet: 2008; 372 9632 40 48 (Pubitemid 351899234)
561. Ell K. et al. Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol: 2008; 26 27 4488 4496
562. Herschbach C., Weis J. Screeningverfahren in der Psychoonkologie Deutsche Krebsgesellschaft. Berlin: 2010
563. Weis J., Domann U. Interventions in the rehabilitation of breast cancer patients - a critical literature review of the state of the art. Rehabilitation: 2006; 45 03 129 145 (Pubitemid 43989319)
564. Mehnert A., Müller D., Lehmann C. et al. Die deutsche Version des NCCN Distress-Thermometers-Empirische Prüfung eines Screening-Instruments zur Erfassung psychosozialer Belastung bei Krebspatienten. ZPPP; 54 03 213 223
565. Holland J. C., Bultz B. D. The NCCN guideline for distress management: a case for making distress the sixth vital sign. J Natl Compr Canc Netw: 2007; 5 01 3 7 (Pubitemid 46212273)
566. Roth A. J. et al. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer: 1998; 82 10 1904 1908 (Pubitemid 28208646)
567. Whooley M. A. et al. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med: 1997; 12 07 439 445 (Pubitemid 27300561)
568. Chochinov H. M. et al. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol: 2011; 12 08 753 762
569. Sommerfeldt S., Ihrig A., Brechtel A. et al. Psychoonkologisches Screening in der Routineversorgung. Psychosomatik und Konsiliarpsychiatrie: 2007; Volume 1, Issue 4: 293 297
570. Weis J., Blettner G., Schwarz R. Psychooncological Care in Germany: Quality and Quantity. Z Psychosom Med Psychother: 2000; 46 01 4 17 (Pubitemid 30066908)
571. Clinical practice guidelines for the psychosocial care of adults with cancer. National Health and Medical Research (NHMRC): 2003